ArticleAmerican heart journal plus : cardiology research and practice2026
Association of statin use and left ventricular function in patients with breast cancer receiving trastuzumab.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: We examined the association between statin use and changes in left ventricular ejection fraction (LVEF) during trastuzumab therapy in women with breast cancer. Methods: This post-hoc analysis of the CHECK HEART-BC study included 215 patients with normal baseline LVEF and 12-month echocardiographic follow-up. We assessed LVEF at baseline and at 3, 6, 9, and 12 months by statin use. Results: Of 215 women, 31 (14%) were receiving statins. Baseline LVEF was comparable between groups. After a similar decline at 3 months, LVEF trajectories diverged, with better preservation among statin users apparent at 9 months and most pronounced at 12 months. Statin use was associated with attenuated LVEF decline over time in an adjusted longitudinal model (interaction estimate, 0.27; standard error, 0.10; Conclusions: Statin use was associated with better LVEF preservation during trastuzumab therapy, particularly during later follow-up. These findings are hypothesis generating and require confirmation in randomized trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.